Cancer clinical trials in the region Bretagne

170 currently recruiting clinical trials
Region Bretagne

Early Access Lymphoma
B cell lymphoma Large B cell lymphoma 2 3 or more
Systemic Treatment-Naive
Hoffmann-La Roche
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access Lymphoma
B cell lymphoma Large B cell lymphoma 1
Systemic Treatment-Naive
Hoffmann-La Roche
Phase 3 Stomach and esophageal cancer #NCT06356311
Stomach Oesogastric junction Esophagus Adenocarcinoma Locally Advanced Metastatic 2 3 or more Immunotherapy Chemotherapy
Systemic Treatment-Naive
Centre Eugene Marquis (Rennes)
Merck Sharp & Dohme LLC
Phase 3 Lung cancer #NCT05899608 #2024-513087-26-00
NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Non-squamous NSCLC Metastatic None Systemic Treatment-Naive
CHU de Rennes - Hôpital Pontchaillou (Rennes), Centre Hospitalier de Cornouaille (Quimper), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest)
Summit Therapeutics
Phase 3 Lung cancer #NCT06908993 #2024-519971-25-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic MET 1 2 Immunotherapy Chemotherapy
ALK BRAF EGFR HER2 KRAS non G12C RET ROS-1 Systemic Treatment-Naive Targeted therapy
Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest)
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Stomach and esophageal cancer #NCT06901531 #2024-519773-19-00
Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
HER2 Immunotherapy Chemotherapy
CARIO Imagerie Médicale site de Plérin (Plérin)
Astellas Pharma Développement mondial, Inc.
Phase 3 Breast cancer #NCT05514054 #2022-501007-28-00
HER2 Negative HR Positive Localized None Hormone therapy
Institut de Cancérologie Radiothérapie Brétillien / CHP Saint Grégoire - Vivalto Santé (Saint-Grégoire), Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest)
Eli Lilly et compagnie